HK1259628A1 - 作為認知和行為障礙藥物的哺乳動物klotho的分泌型剪接變體 - Google Patents

作為認知和行為障礙藥物的哺乳動物klotho的分泌型剪接變體

Info

Publication number
HK1259628A1
HK1259628A1 HK19101816.9A HK19101816A HK1259628A1 HK 1259628 A1 HK1259628 A1 HK 1259628A1 HK 19101816 A HK19101816 A HK 19101816A HK 1259628 A1 HK1259628 A1 HK 1259628A1
Authority
HK
Hong Kong
Prior art keywords
impairments
cognition
behaviour
medicament
splicing variant
Prior art date
Application number
HK19101816.9A
Other languages
English (en)
Inventor
Chillon Rodriguez Miguel
Masso Chacon Anna
BOSCH MERINO Assumpcio
Original Assignee
巴塞羅那自治大學
加泰羅尼亞研究和先進研究基金會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴塞羅那自治大學, 加泰羅尼亞研究和先進研究基金會 filed Critical 巴塞羅那自治大學
Publication of HK1259628A1 publication Critical patent/HK1259628A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK19101816.9A 2015-11-19 2019-01-31 作為認知和行為障礙藥物的哺乳動物klotho的分泌型剪接變體 HK1259628A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15195470 2015-11-19
PCT/EP2016/078320 WO2017085317A1 (en) 2015-11-19 2016-11-21 Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments

Publications (1)

Publication Number Publication Date
HK1259628A1 true HK1259628A1 (zh) 2019-12-06

Family

ID=54704987

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101816.9A HK1259628A1 (zh) 2015-11-19 2019-01-31 作為認知和行為障礙藥物的哺乳動物klotho的分泌型剪接變體

Country Status (10)

Country Link
US (1) US20190030138A1 (zh)
EP (1) EP3377091B1 (zh)
JP (1) JP2019501643A (zh)
CN (2) CN117126829A (zh)
AU (1) AU2016354988A1 (zh)
CA (1) CA3005398A1 (zh)
DK (1) DK3377091T3 (zh)
ES (1) ES2968098T3 (zh)
HK (1) HK1259628A1 (zh)
WO (1) WO2017085317A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3253403B1 (en) 2015-02-06 2021-09-01 The Regents of The University of California Methods and compositions for improved cognition
CN108841868A (zh) * 2018-05-31 2018-11-20 康霖生物科技（杭州）有限公司 一种用于中枢神经系统疾病治疗的基因序列构建体
CN113491764B (zh) * 2020-04-03 2023-09-19 北京大学 Fam19a5的医药用途
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022243519A1 (en) 2021-05-21 2022-11-24 Universitat Autònoma De Barcelona Secreted splicing variant of klotho for treating bone disorders
US20220401583A1 (en) * 2021-06-16 2022-12-22 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
WO2023198828A1 (en) 2022-04-13 2023-10-19 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
WO2024084400A2 (en) * 2022-10-17 2024-04-25 Bio Immunitas Ltd. Alpha 2 macroglobulin, soluble klotho and methods of use thereof
WO2024092238A1 (en) * 2022-10-28 2024-05-02 Unity Biotechnology, Inc. Klotho polypeptide or polynucleotide for improving cognition
EP4378486A1 (en) 2022-12-02 2024-06-05 Universitat Autònoma de Barcelona Secreted splicing variant of klotho for extending lifespan
WO2024115728A1 (en) 2022-12-02 2024-06-06 Universitat Autònoma De Barcelona Secreted splicing variant of klotho for treating muscle disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945506B1 (en) * 1996-12-26 2007-02-28 Kyowa Hakko Kogyo Co., Ltd. Proteine avec une activite de suppression du vieillissement
JP2001072607A (ja) * 1999-09-03 2001-03-21 Kyowa Hakko Kogyo Co Ltd 新規血管内皮機能改善法
EP2152295B1 (en) * 2007-05-08 2018-04-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Klotho protein and related compounds for the treatment of cancer
EP2019143A1 (en) * 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
WO2010071832A1 (en) * 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
WO2014152993A1 (en) * 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Oklahoma Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions
EP3253403B1 (en) * 2015-02-06 2021-09-01 The Regents of The University of California Methods and compositions for improved cognition
ES2750008T3 (es) * 2015-02-27 2020-03-24 Apceth Gmbh & Co Kg Células madre mesenquimatosas modificadas genéticamente que expresan klotho

Also Published As

Publication number Publication date
DK3377091T3 (da) 2024-01-02
CN117126829A (zh) 2023-11-28
EP3377091A1 (en) 2018-09-26
AU2016354988A1 (en) 2018-06-07
US20190030138A1 (en) 2019-01-31
WO2017085317A1 (en) 2017-05-26
ES2968098T3 (es) 2024-05-07
CA3005398A1 (en) 2017-05-26
CN108289933B (zh) 2023-04-28
CN108289933A (zh) 2018-07-17
EP3377091B1 (en) 2023-09-20
JP2019501643A (ja) 2019-01-24

Similar Documents

Publication Publication Date Title
HK1259628A1 (zh) 作為認知和行為障礙藥物的哺乳動物klotho的分泌型剪接變體
IL291474A (en) Architectures and methods for emitting different wavelengths of light from waveguides
HK1255699A1 (zh) Kras表達的調節劑
IL283582A (en) ror - gamma modulators
IL275752B (en) Soft enteric capsules of fumarate esters with controlled release
EP3234673A4 (en) Ruggedized optical fiber connection structures and assemblies
PL3143444T3 (pl) Zespoły przewodów światłowodowych do zakańczania przewodu światłowodowego i sposoby ich wytwarzania
EP2893949A4 (en) CATHETER WITH GLASS FIBERS AND A CAMERA
EP3125959B8 (en) Electrospun biocompatible fiber compositions
SG11201610604RA (en) Optical coupler
EP2968347A4 (en) MODULATORS OF THE EIF2ALPHA SIGNAL PATH
PL3418786T3 (pl) Złącze światłowodowe i łącznik światłowodowy
GB201317400D0 (en) Dental Kit-of-parts and Method of assembling the same
EP2967833A4 (en) FACED FIBER AND METHOD FOR USE THEREOF
IL248892B (en) Optical connection of optical fibers to a lattice connector
EP3100087A4 (en) Design and manufacture of multi-mode optical fibers
ZA201703679B (en) TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
IL251402A0 (en) Soft capsules for controlled intestinal release of fumarate esters
EP3212170A4 (en) Implantable medical devices for extended release of therapeutic agents
EP2847628A4 (en) BARBELL OPTIC FIBER AND METHOD FOR MANUFACTURING THE SAME
IL274494A (en) Esters of dihydrotetrabenazine
EP3525772A4 (en) FORMULATIONS FOR THE ENTERIC ADMINISTRATION OF THERAPEUTIC AGENTS
EP3196683A4 (en) Optical fiber connecting structure and optical fiber connector
IL250086A0 (en) Formulations of biological substances for insertion into a blister
DK3193867T3 (da) Okulære formuleringer til lægemiddelfremføring og beskyttelse af øjets forreste segment